APA (7th ed.) Citation

Goswami, T., Lamb, L., Rochlin, K., & Nabors, B. (2023). CTIM-35. INB-400 PHASE 1B/2 DRUG RESISTANT IMMUNOTHERAPY WITH ACTIVATED, GENE MODIFIED ALLOGENEIC OR AUTOLOGOUS ΓΔ T CELLS IN COMBINATION WITH MAINTENANCE TEMOZOLOMIDE RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-oncology (Charlottesville, Va.), 25(Supplement_5), v70. https://doi.org/10.1093/neuonc/noad179.0275

Chicago Style (17th ed.) Citation

Goswami, Trishna, Lawrence Lamb, Kate Rochlin, and Burt Nabors. "CTIM-35. INB-400 PHASE 1B/2 DRUG RESISTANT IMMUNOTHERAPY WITH ACTIVATED, GENE MODIFIED ALLOGENEIC OR AUTOLOGOUS ΓΔ T CELLS IN COMBINATION WITH MAINTENANCE TEMOZOLOMIDE RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA." Neuro-oncology (Charlottesville, Va.) 25, no. Supplement_5 (2023): v70. https://doi.org/10.1093/neuonc/noad179.0275.

MLA (9th ed.) Citation

Goswami, Trishna, et al. "CTIM-35. INB-400 PHASE 1B/2 DRUG RESISTANT IMMUNOTHERAPY WITH ACTIVATED, GENE MODIFIED ALLOGENEIC OR AUTOLOGOUS ΓΔ T CELLS IN COMBINATION WITH MAINTENANCE TEMOZOLOMIDE RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA." Neuro-oncology (Charlottesville, Va.), vol. 25, no. Supplement_5, 2023, p. v70, https://doi.org/10.1093/neuonc/noad179.0275.